Literature DB >> 35138606

Role of diabetes mellitus in the clinical course and outcome of SARS-CoV-2 infected patients.

Helena C Maltezou1, Androula Pavli2, Paraskevi Tsonou2, Asimina Balaska3, Vasilios Raftopoulos4, Kalliopi Papadima5, Anastasia Andreopoulou5, Anastasios Tentolouris6, Maria N Gamaletsou7, Nikolaos V Sipsas7, Nikolaos Tentolouris6.   

Abstract

PURPOSE: Our aim was to study patients with diabetes mellitus and SARS-CoV-2-infection diagnosed during the first pandemic wave in Greece.
METHODS: Cases were retrieved from the national database of SARS-CoV-2 infections.
RESULTS: We studied 2624 SARS-CoV-2 infected cases, including 157 with diabetes. Patients with diabetes more often had other comorbidities (68.8 vs. 24.1%; p-value < 0.001). Among patients with diabetes, 149 (94.9%) developed symptomatic disease (COVID-19) compared to 1817 patients (73.7%) without diabetes (p-value < 0.001). A total of 126 patients with diabetes and COVID-19 were hospitalized and 41 died (27.5% case-fatality rate compared to 7.5% among patients without diabetes; p-value < 0.001). Patients with diabetes more often were hospitalized, developed complications, were admitted to the intensive care unit (ICU), received invasive mechanical ventilation, and died compared to patients without diabetes (p-values < 0.001 to 0.002 for all comparisons). Multivariate logistic regression analyses revealed that diabetes, having other comorbidities, and older age were significantly associated with higher risk for hospitalization, ICU admission, invasive mechanical ventilation, and death, and that obesity was significantly associated with higher risk for hospitalization, ICU admission, and mechanical intubation, while female gender protected against these outcomes.
CONCLUSION: COVID-19 is associated with increased rates of serious morbidity and adverse outcome in patients with diabetes and represents a severe illness for them.
© 2022. Hellenic Endocrine Society.

Entities:  

Keywords:  COVID-19; Clinical course; Comorbidities; Diabetes mellitus; Outcome; SARS-CoV-2

Mesh:

Year:  2022        PMID: 35138606     DOI: 10.1007/s42000-021-00342-x

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  1 in total

Review 1.  Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications.

Authors:  Ioannis P Trougakos; Kimon Stamatelopoulos; Evangelos Terpos; Ourania E Tsitsilonis; Evmorfia Aivalioti; Dimitrios Paraskevis; Efstathios Kastritis; George N Pavlakis; Meletios A Dimopoulos
Journal:  J Biomed Sci       Date:  2021-01-12       Impact factor: 8.410

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.